 NEW YORK--BUSINESS WIRE--WaterMill Asset Management Corp. together with its affiliates, WaterMill or we, which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3 of the outstanding shares of Ziopharm Oncology, Inc. NASDAQ: ZIOP Ziopharm or the Company, today issued the below letter to shareholders in support of the proposals included in its definitive consent statement filed with the U.S. Securities and Exchange Commission o 